Bristol-Myers Squibb rated buy with strong Q2, 4.23% dividend, and raised 2026 sales outlook.

Bristol-Myers Squibb (BMY) is reaffirmed as a buy due to its attractive valuation and a high dividend yield of 4.23%. The company reported strong Q2 earnings, raised its full-year 2026 sales guidance, and showed robust growth in both legacy and new products. Despite potential challenges from patent expirations and expected EPS declines after 2026, BMY benefits from strong free cash flow and recent positive EPS revisions. Technical support at the 200-day moving average and solid cash flow suggest resilience, though investors should watch resistance at $63 and pipeline execution closely.

Following Bristol-Myers Squibb's reaffirmed buy rating and strong Q2 earnings, the stock trades at USD 59.70 on Pluang as of Oct 08, 2026 06:31 WIB, showing a modest 0.18% increase over one day. The dividend yield remains attractive at 4.23%, while the market cap stands at $121.73 billion. Despite a high sell order activity of 93%, the stock's 52-week range between $42.60 and $68.09 highlights its resilience in the health sector.